Blood group antigen a and flow cytometric analysis in resected early-stage non-small cell lung cancer

被引:0
|
作者
Graziano, SL
Tatum, AH
Gonchoroff, NJ
Newman, NB
Kohman, LJ
机构
[1] VET AFFAIRS MED CTR,DEPT PATHOL,SYRACUSE,NY 13210
[2] VET AFFAIRS MED CTR,DEPT SURG,SYRACUSE,NY 13210
[3] SUNY HLTH SCI CTR,SYRACUSE,NY 13210
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The loss of blood group antigen A on tumor tissue has been reported to be a strong adverse prognostic marker for patients with resected non-small cell lung cancer (NSCLC), Results have varied with respect to the prognostic significance of flow cytometric data, We sought to confirm the prognostic significance of blood group antigen A loss and flow cytometry in a large cohort of patients with early-stage NSCLC. Two hundred and sixty patients with surgically resected stage I(n = 193) and II (rt = 67) NSCLC with at least a 5-year follow-up were identified, Using paraffin-embedded primary tumor, immunohistochemical stains for blood group antigen A were performed on 90 patients with blood type A or AB, The DNA index and percentage of cells in S phase were successfully obtained on 188 and 152 patients, respectively, The median survival time of the patients with primary tumors negative for blood group antigen A was 38 months (II = 36), compared with 98 months (n = 54) for those with antigen A-positive tumors (P < 0.01), The median disease-free survival times for antigen A-negative and -positive tumors were 26 months and 98 months, respectively (P < 0.01), The median survival time of the patients with aneuploid tumors was 51 months (n = 131), compared with 50 months (n = 57) for those with diploid tumors (P = 0.42), The median survival time of the patients with S phase >8% was 44 months (n = 105), compared with 60 months (n = 47) for those with S phase less than or equal to 8% (P = 0.18), Multivariate analysis showed that the loss of antigen A, higher N and T stages, and the presence of mucin predicted for poorer disease-free and overall survival, In the subgroup of patients with blood group A or AB, the loss of antigen was the most powerful negative predictor of survival, Aneuploidy and percentage of cells in S phase were not of prognostic significance in this group of patients with resected stage I and II NSCLC. The value of blood group antigen A analysis needs to be evaluated in larger and prospective studies of early-stage NSCLC, Alteration of blood group antigen cell surface expression may represent an important marker for more aggressive biological and metastatic behavior in NSCLC.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [41] Role of Segmentectomy in Treatment of Early-Stage Non-Small Cell Lung Cancer
    Hennon, Mark
    Landreneau, Rodney J.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (01) : 59 - 63
  • [42] Resectability versus Operability in Early-Stage Non-Small Cell Lung Cancer
    Streit, Arthur
    Lampridis, Savvas
    Seitlinger, Joseph
    Renaud, Stephane
    Routledge, Tom
    Bille, Andrea
    CURRENT ONCOLOGY REPORTS, 2024, 26 (01) : 55 - 64
  • [43] Survivin gene expression in early-stage non-small cell lung cancer
    Falleni, M
    Pellegrini, C
    Marchetti, A
    Oprandi, B
    Buttitta, F
    Barassi, F
    Santambrogio, L
    Coggi, G
    Bosari, S
    JOURNAL OF PATHOLOGY, 2003, 200 (05): : 620 - 626
  • [44] Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer
    Jacob Y. Shin
    Ja Kyoung Yoon
    Gaurav Marwaha
    Lung, 2018, 196 : 351 - 358
  • [45] Carbonic anhydrase IX in early-stage non-small cell lung cancer
    Kim, SJ
    Rabbani, ZN
    Vollmer, RT
    Schreiber, EG
    Oosterwijk, E
    Dewhirst, MW
    Vujaskovic, Z
    Kelley, MJ
    CLINICAL CANCER RESEARCH, 2004, 10 (23) : 7925 - 7933
  • [46] Prognostic Impact of Histology on Early-Stage Non-small Cell Lung Cancer
    Maeda, Ryo
    Yoshida, Junji
    Ishii, Genichiro
    Hishida, Tomoyuki
    Nishimura, Mitsuyo
    Nagai, Kanji
    CHEST, 2011, 140 (01) : 135 - 145
  • [47] Nonintubated thoracoscopic surgery for early-stage non-small cell lung cancer
    Hung, Wan-Ting
    Cheng, Ya-Jung
    Chen, Jin-Shing
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2020, 68 (07) : 733 - 739
  • [48] Proton therapy for early-stage non-small cell lung cancer (NSCLC)
    Gomez, Daniel R.
    Li, Heng
    Chang, Joe Y.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (02) : 199 - 204
  • [49] Resectability versus Operability in Early-Stage Non-Small Cell Lung Cancer
    Arthur Streit
    Savvas Lampridis
    Joseph Seitlinger
    Stéphane Renaud
    Tom Routledge
    Andrea Bille
    Current Oncology Reports, 2024, 26 : 55 - 64
  • [50] Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer (NSCLC)
    Ludovini, Vienna
    Darwish, Samir
    Ragusa, Mark
    Pistola, Lorenza
    Rulli, Eliana
    Di Carlo, Luciana
    Tofanetti, Francesca R.
    Ferraldeschi, Massimiliano
    Daddi, Giuliano
    Tonato, Maurizio
    ANNALS OF ONCOLOGY, 2004, 15 : 189 - 189